Category: Asahi Kasei Corp.
Zoll Medical wins 510(k) clearance for its AED Plus CPR-assist technology.
Asahi Kasei (TYO:3407) subsidiary Zoll Medical won 510(k) clearance from the FDA for its fully-automated AED Plus device, which improves on the former semi-automatic model.
The new automated external defibrillator allows emergency responders to pre-program a shock instead of pushing the "shock" button.
Zoll Medical breaks into the Japanese market with its temperature regulating device, the first of its kind to win regulatory approval in the Land of the Rising Sun.
Japan's Ministry of Health, Labour and Welfare granted Shonin approval to Zoll Medical's intravascular temperature managment device for treating patients with high fevers and brain damage.
The Chelmsford, Mass.-based medical device company's temperature regulating device is designed to control high fevers in patients with neurological impairment. It provides direct cooling and warming to the circulatory system via a ballon catheter.
Zoll CEO Rick Packer says the medical device tax will lead to higher costs, fewer jobs and more off-shoring both for his company and for the med-tech industry.
Boston Scientific's Lotus TAVI system minimizes leakage in an early trial, St. Jude Medical gains on a Goldman upgrade and the SEC closes a probe of Zoll's Middle East sales just ahead of $2.3B Asahi merger.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
NxStage Medical posts a double-digit top-line increase and narrows its 1st-quarter losses but closes down more than 3%, possibly due to a debt-to-equity swap by Asahi Kasei.
Investors declined to reward NxStage Medical (NSDQ:NXTM) today for another in a string of solid quarters, sending share prices down YY% despite higher sales, narrowed losses and re-affirmed guidance.
Asahi Kasei ends the 2nd phase of its $2.2 billion buyout of Zoll Medical, leaving it with more than 93% of the automated external defibrillator maker.
Asahi Medical completes the first stage of its $2.3 billion acquisition of Zoll Medical, paying $93 apiece for 93.8% of Zoll's outstanding shares and launching a 3-day offering period for the rest.
Chelmsford, Mass.-based resuscitation device maker Zoll Medical (NSDQ:ZOLL) sealed the deal with Japan's Asahi Kasei Corp. (TYO:3407) over the weekend.
